JCXH G
Alternative Names: JCXH-GLatest Information Update: 05 Dec 2022
At a glance
- Originator Immorna
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Palmoplantar pustulosis; Scars
Most Recent Events
- 24 Nov 2022 Preclinical trials in Scars (Prevention) in USA (Parenteral), prior to November 2022, (Immorna pipeline, November 2022)
- 24 Nov 2022 Preclinical trials in Unspecified in USA (Parenteral), prior to November 2022, (Immorna pipeline, November 2022)